Zacks Research Issues Positive Forecast for TSE:BHC Earnings

Bausch Health Companies Inc. (TSE:BHC) – Zacks Research raised their Q3 2028 earnings per share estimates for shares of Bausch Health Companies in a research note issued to investors on Tuesday, September 22nd. Zacks Research analyst Team now expects that the company will post earnings of $1.14 per share for the quarter, up from their previous forecast of $1.13. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share.

Bausch Health Companies (TSE:BHC) last announced its quarterly earnings data on Wednesday, July 29th. The company reported C$1.79 earnings per share (EPS) for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%.The company had revenue of C$4.05 billion for the quarter.

Separately, Jefferies Financial Group upgraded shares of Bausch Health Companies to a “hold” rating in a research note on Wednesday, July 22nd. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Bausch Health Companies currently has a consensus rating of “Hold”.

Bausch Health Companies Price Performance

Shares of BHC opened at C$8.27 on Friday. The company has a market cap of C$3.09 billion, a price-to-earnings ratio of -2.81, a PEG ratio of 0.21 and a beta of 0.71. Bausch Health Companies has a 1-year low of C$6.10 and a 1-year high of C$11.08. The company’s fifty day simple moving average is C$8.54 and its 200 day simple moving average is C$7.69. The company has a current ratio of 1.44, a quick ratio of 0.58 and a debt-to-equity ratio of -1,173.29.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.